Effect of the novel galectin-3 blocker, Gal3M, on the efficacy and reduction of toxicity of proteasome inhibitors for the treatment of multiple myeloma.

• DOI: 10.1200/jco.2014.32.15_suppl.e19581
• Publication Date: 2019-01-03T22:36:52Z
• Authors: Jehanzeb Riaz; Rashmi Verma; Leonardo Mirandola; Jose A. Figueroa; Everardo Cobos; Diane Duyen Thuy ...; Amardeep Singh Au...; Venu Konala; Marjorie Jenkins; Yuefei Yu; Saba Radhi; Kayley Trotter; Lukman Aderoju Ti...; Fred Hardwick; Nicholas C. D'Cunha; Michela Colombo; Scott Dahlbeck; Fabio Grizzi; Maurizio Chiriva-...
• Keywords: Pomalidomide

e19581 Background: Multiple myeloma (MM) is a neoplastic plasma cell disorder which results in multiple organ failure. Anemia, hypercalcemia, renal failure and skeletal lesions are the most relevant morbidities associated with MM. The treatment of MM includes chemotherapy, hematopoietic stem transplantation, immune modulating treatments proteasome inhibitors. Carfilzomib new inhibitor that also has anti osteoclastogenic effects. Treatment Carfilzomob both cardiac toxicity, mostly mediated by fibrotic tissue damage. Galectin-3 hyper-expression been implicated development congestive heart acute We aimed to test efficacy combined therapy novel dominant-negative Galectin-3, namely Gal3M, for Methods: used 5TGM1 murine syngeneic model In order monitor tumor growth vivo C57Bl/KaLwRij mice, we measured levels circulating IgG2b cancer testis antigen, SP17 ELISA, Western blot RT-PCR. cells was monitored viability chemotaxis assays. Results: Our show Gal3M increased therapeutic vitroin carrying causing 85% decline growth. able counter toxic effects Carfizomib on kidney decreasing deposition active caspase 3 positive cells. On other hand, prevent increase potential caused Gal3M. Conclusions: data represent rationale use not only block but toxicity